Nimesulide Hexal AG is applicable within clinical settings that involve acute or disruptive symptom patterns, and is used for providing symptomatic relief across domains characterized by symptoms related to physical discomfort, inflammatory states, and systemic imbalance. Its therapeutic focus is on short-term symptomatic assistance during episodes where symptoms create noticeable interference with daily comfort and stability.

The medication is applied across domains where additional symptomatic support is needed, including presentations such as acute pain syndromes, painful osteoarthritis (for symptomatic management of flares), and primary dysmenorrhoea.

It is relevant in clinical contexts involving heightened systemic burden, such as following post-traumatic injuries or during recovery from minor surgical procedures. The drug offers symptomatic relief that helps ease the overall symptom burden, which may help patients cope more steadily with symptom fluctuations and support general well-being during symptomatic phases.

---

Quick Fact: Relief for Acute Discomfort
Nimesulide Hexal AG may assist with acute pain and is relevant for addressing inflammatory swelling and fever that accompany these episodes.

Regulatory References

1. European Medicines Agency official therapeutic indications

Nimesulide Hexal AG is permitted for use by adults and adolescents aged 12 years and older. The official regulatory profile establishes conditional use for eligible patients: treatment is strictly limited to a maximum duration of 15 days and the medicine must only be prescribed as a second-line treatment. No dosage adjustment is necessary for elderly patients or those with mild to moderate renal impairment.

Populations Who Must Not Use the Medicine (Contraindications)

Official labeling strictly prohibits Nimesulide Hexal AG in several groups. The medicine is contraindicated for children under 12 years of age and for women during the third trimester of pregnancy or when breastfeeding. It is also not recommended for women who are attempting to conceive.

Condition-Specific Exclusions:

Eligibility is entirely removed for patients with conditions affecting major organ function or bleeding risk. Use is contraindicated in individuals with any degree of hepatic impairment (including a history of adverse liver reactions to nimesulide), severe renal impairment (creatinine clearance less than 30 ml/min), or severe heart failure. Patients with active gastrointestinal bleeding, a history of recurrent peptic ulcers, or severe coagulation disorders are also strictly ineligible. The medicine is also prohibited for those with a known hypersensitivity to nimesulide or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Interactions with other medicines and products

Official regulatory information outlines several clinically significant constraints regarding the co-administration of Nimesulide Hexal AG with other substances. These constraints are based on documented changes in efficacy and safety when certain combinations are used.

Documented Interacting Substances and Product Classes

Interacting Product Category	Specific Interacting Medicines Listed
Anticoagulants and Antiplatelet agents	Warfarin, Acetylsalicylic acid
Diuretics	Furosemide
Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Other NSAIDs (unspecified)
Known Hepatotoxic drugs	Alcohol (Ethanol)

Interaction-Related Restrictions and Caution

Combination with Warfarin or similar anticoagulant agents or Acetylsalicylic acid is not recommended due to an increased risk of bleeding complications. This co-administration is contraindicated in patients with severe coagulation disorders. If combination with anticoagulants cannot be avoided, official documentation requires close monitoring of anticoagulant activity.

Simultaneous use of different NSAIDs is not recommended.

Concomitant administration with known hepatotoxic drugs and alcohol must be avoided during treatment with Nimesulide Hexal AG. The product has also been shown to transiently decrease the effect of the diuretic Furosemide on sodium excretion. Use with Furosemide requires caution in susceptible renal or cardiac patients.

Targeted Enzyme Inhibition in Inflammation

Nimesulide primarily functions by preferentially and reversibly inhibiting the Cyclooxygenase-2 ( COX-2) enzyme. This action significantly reduces the synthesis of pro-inflammatory mediators, notably Prostaglandin E2 ( PGE2), a mediator known to sensitize nociceptors and elevate the body's thermal set-point. This core molecular intervention in the arachidonic acid cascade results in the modulation of the pathways governing nociceptor sensitization and thermal regulation.

---

Modulation of Non-Prostanoid Systems

Beyond its primary enzyme target, the drug engages a broader set of mechanisms by modulating key inflammatory cascades. It is relevant in systems where targeted pathway adjustment is required, notably through the inhibition of Matrix Metalloproteinases ( MMPs) and the suppression of inflammatory cytokines ( TNF-alpha, IL-6). These complementary actions are characterized by the suppression of cellular immune responses and the inhibition of matrix degradation.

---

Reversible and Preferential Binding

The mechanism is characterized by a reversible interaction with COX-2 and a preferential binding profile over the constitutive COX-1 enzyme. This pattern means the activity is focused on inducible inflammatory responses, resulting in the acute and short-term attenuation of upregulated physiological signaling within targeted pathways.

Official Administration Guidelines

Instructions for the proper use of Nimesulide Hexal AG are defined by clinical standards and approved documentation.

Administration Scope	Detail
Route of Administration	Oral use (tablets or granules for oral suspension).
Standard Dosing Schedule	100 mg per dose.
Maximum Daily Dose	200 mg (100 mg twice a day).
Timing in Relation to Meals	Must be taken after meals (post cibum).
Maximum Course Duration	Limited to a maximum of 15 days.

Dosing and Procedural Rules

The standard oral dosage of Nimesulide Hexal AG for adults is 100 mg taken twice daily. It is mandated to use the minimum effective dose for the shortest possible duration of treatment, which must not exceed 15 days. The dose should be administered after food. If using the granular dosage form, the contents of the sachet must be dissolved in water before oral intake.

Population-Specific Use

Administration rules restrict the use of Nimesulide based on age and patient health status. The medicine is contraindicated (must not be used) in children under 12 years of age. Furthermore, patients with severe renal impairment (Creatinine Clearance <30 mL/min) or any sign of hepatic impairment are restricted from using this medicine. For elderly patients and adolescents (12 to 18 years), no dosage adjustment is typically required from the standard adult dose.

Research Evidence / Overview of Studies for Nimesulide Hexal AG

The evidence for this medication comes from research focused on its use in specific, acute symptom patterns. The studies conducted meet the requirements set by regulatory agencies and aim to understand how the medicine was evaluated in specific clinical situations. This overview summarizes the structure and focus of that research without offering advice or clinical interpretation.

---

Evidence from Studies for Acute Pain

Research exploring short-term symptom changes was largely conducted through Randomized Controlled Trials (RCTs). These trials compared the medicine's use to either an inactive substance (placebo) or to other treatments frequently studied for these conditions. The studies focused on outcomes related to physical discomfort, primarily focusing on patient-reported outcomes describing perceived discomfort in conditions like post-traumatic injuries or pain following minor surgical procedures.

Findings describe patterns observed in the studies related to the speed and overall extent of symptom change measured during the short treatment periods. This research provides context but not individual predictions, and findings help contextualize how patients reported their experience under the specific conditions of the trials.

---

Evidence from Studies for Primary Dysmenorrhoea

For primary dysmenorrhoea, studies explored short-term symptom changes associated with this condition, which is characterized by fluctuating or episodic manifestations. The primary research consists of Randomized Controlled Trials (RCTs) monitoring patient-reported outcomes describing perceived discomfort related to menstrual pain.

Data show patterns related to symptom changes during the acute painful episode. Some research also examined outcomes monitoring physiological strain, such as measuring specific biological markers related to the inflammatory process in the body.

---

Duration of Evidence and Research Gaps

A defining characteristic of the research evidence is that it is primarily relevant in trials assessing short-term or episodic symptom patterns. Regulatory documentation has established a maximum treatment period of 15 consecutive days. This means the available evidence for how the medicine was observed in studies measuring symptoms is based entirely on use within this narrow window.

The research exploring short-term symptom changes was graded as High level of evidence for the outcomes measured in the acute setting. However, the most significant research limitation is that long-term effects are not fully established, and there is limited information for long-term outcomes relevant to managing chronic or sustained conditions.

Common questions about Nimesulide Hexal AG (FAQ)

Q: How long does it typically take for Nimesulide Hexal AG to start working?

Regulatory documents describe the medication as having a rapid onset of action. Studies indicate that noticeable reductions in pain and inflammation are typically observed within approximately 15 minutes following intake.

Q: Is Nimesulide Hexal AG used for treating fever?

Official product documentation states that Nimesulide Hexal AG possesses properties that help relieve pain, reduce inflammation, and lower fever. The medicine's effect of reducing fever is described using the term 'antipyretic action.'

Q: Are there any special warnings about taking Nimesulide Hexal AG?

Regulatory documents contain specific warnings, particularly concerning liver health. Official warnings specify that immediate discontinuation is required if symptoms of liver injury, such as persistent nausea, yellowing of the skin (jaundice), or fatigue, appear. Official warnings also outline restrictions for patients with pre-existing severe heart, kidney, or certain bleeding conditions.

Q: Can Nimesulide Hexal AG interact with blood pressure medicine?

Official safety information notes that Nimesulide Hexal AG can interact with certain types of blood pressure medicines. Specifically, regulatory warnings indicate the medicine may alter the action of diuretics, such as Furosemide. Caution is generally required when using it alongside any medication known to affect the body’s kidney function or blood flow.

Q: Is Nimesulide Hexal AG suitable for older adults?

Regulatory guidance generally does not require a change in the standard dose for elderly patients. However, the official product information advises that this population should be treated with caution. This is due to a documented potential for increased susceptibility to possible adverse effects compared to younger adults.

Q: What is the risk of allergic reactions to Nimesulide Hexal AG?

Official documentation states that a known hypersensitivity (severe allergy) to Nimesulide or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is a condition that prohibits use. Undesirable skin effects, such as a rash or, very rarely, urticaria (hives), are described in regulatory safety reports.

Q: Can Nimesulide Hexal AG affect kidney function?

Regulatory safety information confirms that the medicine carries a potential risk for renal dysfunction (impaired kidney function). Due to this risk, the drug is strictly contraindicated for individuals who already have severe kidney impairment.

Q: Is Nimesulide Hexal AG ever used for long-term conditions like arthritis?

Official regulatory guidance limits the use of this medicine to a maximum duration of 15 consecutive days. The available research evidence is similarly focused on acute, short-term symptom patterns. Therefore, long-term effects of the medicine are not fully established or recommended in regulatory documents.

Q: Are there certain groups of people who are more likely to experience side effects?

Official warnings indicate that certain groups may have a higher susceptibility to adverse effects. These groups include elderly patients and individuals with existing severe conditions affecting the heart or kidney. Those with a history of gastrointestinal problems or bleeding are also noted to be at increased risk.

Q: What does 'selective COX-2 inhibitor' mean in simple terms?

The term means the medicine is designed to mainly target one specific enzyme in the body, known as Cyclooxygenase-2 (COX-2). This enzyme is largely responsible for creating chemical signals that cause pain and inflammation. By preferentially targeting COX-2, the drug is designed to have less effect on the COX-1 enzyme, which plays a protective role in the stomach lining.

Q: How is Nimesulide Hexal AG different from traditional NSAIDs?

Nimesulide Hexal AG is categorized by its preferential inhibition of the COX-2 enzyme. This specific mechanism is what distinguishes it from traditional, or non-selective, NSAIDs. Non-selective NSAIDs generally inhibit both the COX-1 and COX-2 enzymes simultaneously.

Q: What is the process for monitoring the safety of Nimesulide Hexal AG?

The safety profile of the medicine is continuously monitored by both national and European regulatory authorities through a process called pharmacovigilance. These agencies regularly evaluate all reported adverse drug reactions and update the product information as necessary based on new safety data.

Q: Is Nimesulide Hexal AG known to be addictive?

According to official classification, Nimesulide Hexal AG is a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not designated by regulatory bodies as a controlled substance and does not carry warnings regarding the potential for addiction or physical dependence.

Q: Is it described in official sources that Nimesulide Hexal AG can cause skin reactions?

Yes, official documents describe that undesirable effects on the skin and subcutaneous tissues can occur. These effects include a rash and, very rarely, more significant reactions such as urticaria (hives) or peeling. Regulatory warnings also include precautions against photosensitivity, which is a reaction to sunlight.

Q: Does Nimesulide Hexal AG interact with birth control pills?

Regulatory information advises that caution is needed when Nimesulide Hexal AG is used alongside other medicines that can affect the liver. Some safety reports have examined the potential for an increased risk of adverse liver effects when Nimesulide is used at the same time as oral contraceptives.

Q: Is it normal to feel tired when using Nimesulide Hexal AG?

Official safety information lists somnolence (drowsiness) as a possible undesirable effect. However, fatigue is also specifically listed as a symptom that could indicate a more serious issue, such as liver injury. If fatigue is persistent or severe, this is a symptom that requires immediate medical attention according to regulatory warnings.

Q: Are there any special considerations for people with asthma who use Nimesulide Hexal AG?

Yes, there are special considerations. Official documents state that the medicine is generally contraindicated (should not be used) in patients with a history of bronchial asthma and intolerance to other NSAIDs. Additionally, bronchospasm, which is a sudden tightening of the muscles around the airways, is listed as a possible undesirable effect.

Storage and Disposal of Nimesulide Hexal AG

The medicine must be stored under specific conditions to ensure product integrity up to the labeled expiry date. Store the product below 25 C or 30 C, depending on the specific regulatory document, and protect it from light and moisture.

Handling and Safety

The product must be kept in its original container and should not be used after the expiry date printed on the packaging. To prevent accidental poisoning, it is a mandatory safety provision to keep Nimesulide Hexal AG out of the sight and reach of children.

Disposal Instructions

Regulatory requirements prohibit discarding this medicine via household waste or wastewater. Unused or expired medication must be disposed of by taking it to a pharmacist or an approved waste disposal plant in accordance with national and local regulations.